From the development of new drugs designed by applying artificial intelligence to digital health applications that allow patients to better manage their diseases, data science innovations are driving a real impact in society. We believe that this is only the beginning.

Because we believe data science has the potential to transform patient care, we are partnering and investing in early stage initiatives that share our vision.

INVESTMENT & PARTNERSHIP PHILOSOPHY

We are specialized in accelerating healthcare innovation by developing win-win collaborative relationships with world class academia, government institutions and research centers dedicated to transformative research. Our focal point is innovation. We seek to participate and invest in projects based on scientific excellence and a passion for creating new and differentiated approaches that map out the therapeutic future. We work together with researchers to fulfill the initial market proof-of-concept.

Learn more

PORTFOLIO

As of June 2024, our investment portfolio includes the following organizations:

Accure therapeutics develops new first-in-class disease-modifying for diseases of the nervous system including multiple sclerosis, optical neuritis, Parkinson’s disease and epilepsy.

Learn more.


Chemotargets is a global leader in AI and predictive analytics solutions for the discovery of better and safer drugs.
Learn more.


QUIBIM applies AI and advanced computational models to radiological images to objectively measure changes produced by a lesion or by a pharmacological treatment, offering additional quantitative information to the qualitative approach of radiology.
Learn more.


Bioinfogate, now part of Clarivate Analytics, works to solve unmet medical needs with innovative knowledge management tools and analytics software solutions to support the discovery and development of better and safer drugs.
Learn more.


Kiin’s (formerly Virtual Body Works) unique approach uses immersive virtual reality and AI to facilitate implicit learning and enable people to experience discrimination and bias from others’ perspectives.

Learn more.


Connecta Therapeutics is focusing on the clinical development of CTH120, a new first-in-class molecule for treating fragile X syndrome.
Learn more.


MedBioinformatics aims to exploit biomedical data to support drug discovery pipelines and to enhance biomedical research.
Learn more.


Follow-app care uses population level insights on behaviour and communication patterns to drive up patient experience and engagement.
Learn more.


NanoBots platform enables the design, of novel therapeutic candidates with unique properties to cross biological barriers and accumulate in target cells.
Learn more.

AWARDS

PROUS INSTITUTE – OVERTON AND MEYER AWARD FOR NEW TECHNOLOGIES IN DRUG DISCOVERY

The Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery was established in 2004 to encourage innovation and investigation in technologies related to drug discovery. The Award is given biennially to acknowledge the discovery, evaluation or use of a new technology, and consists of a cash prize, a diploma and an invitation to present a lecture at an EFMC-ISMC symposium. Previous winners can be seen here.

THE UNIQUENESS AND CORE COMPETENCIES THAT ALLOW US TO SUCCESSFULLY UNDERTAKE THESE PARTNERSHIPS REFLECT OVER 60 YEARS OF EXPERIENCE CREATING AND MANAGING BIOMEDICAL KNOWLEDGE INITIATIVES

LATEST NEWS